Search
Now showing items 1-3 of 3
Novel monoamine oxidase inhibitors: a patent review (2012-2014)
(Taylor & Francis, 2015)
Introduction: Monoamine oxidase (MAO) inhibitors, despite the initial pharmacological interest, are used in clinic for their antidepressant effect and in the management of Parkinson symptoms, due to the established ...
MAO inhibitors and their wider applications: a patent review
(Taylor & Francis, 2018)
Introduction: Monoamine oxidase (MAO) inhibitors, after the initial ‘golden age’, are currently used as third-line antidepressants (selective MAO-A inhibitors) or clinically enrolled as co-adjuvants for neurodegenerative ...
Therapeutic potential of selectively targeting the α2c-adrenoceptor in cognition, depression, and schizophrenia: new developments and future perspective
(Frontiers Media, 2017)
α2A- and α2C-adrenoceptors (ARs) are the primary α2-AR subtypes involved in central nervous system (CNS) function. These receptors are implicated in the pathophysiology of psychiatric illness, particularly those associated ...